Clinical observation of hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with advanced ovarian cancer#br#

doi:10.3969/j.issn.10073205.2017.12.012

Abstract

Abstract: ［Abstract］〓Objective〖HTSS〗〓To evaluate the effect of hyperthermic intraperitoneal chemotherapy with paclitaxel after cytoreductive surgery(CRS) in patients with advanced ovarian cancer.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓A total of 46 cases of advanced(stage Ⅲ-Ⅳ) ovarian cancer patients were included in our study, 23 cases in study group and 23 cases in control group randomly. The study group was treated by hyperthermic intraperitoneal chemotherapy with paclitaxel and venous chemotherapy with oxaliplatin and docetaxel regimen after CRS. While the control group was treated by venous chemotherapy with oxaliplatin and docetaxel regimen after CRS only.Clinical treatment results for toxicity and adverse reactions, curative effects, remission rate of tumor, controlled rate of ascites, quality of life, and progressionfree survival(PFS) were compared and analyzed after treatment.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓The differences of the total remission rate of tumor and curative effects between two groups were not statistically significant(P＞005). The controlled rate of ascites and KPS score in the study group were all better than patients in the control group(P＜005). The PFS is also beteer than that of the control group(P＜005).The differences in the rate of toxicity and adverse reactions between the study group and the control group were not statistically significant(P＞005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Applying the hyperthermic intraperitoneal chemotherapy with paclitaxel to treat advanced ovarian cancer after CRS can improve the controlled rate of ascites, KPS score, PFS and with little toxicity and adverse reactions.

Key words: ovarian neoplasms, chemotherapy, cancer, regional perfusion, paclitaxel

LI Nan1, SUN Yanan2, YANG Liang3, CHEN Suqin1. Clinical observation of hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with advanced ovarian cancer#br#[J]. Journal of Hebei Medical University, doi: 10.3969/j.issn.10073205.2017.12.012.

[1]	WANG Lu, SHAN Jia-jia. Mechanisms of miRNA promoting invasion and metastasis in ovarian cancer [J]. Journal of Hebei Medical University, 2023, 44(7): 824-829.
[2]	ZHAO Huan, PANG Yi-cun, ZHAO Jun, XING Hui-min, MA Xiao-lin, HUO Cui-min. The effect of SPHK1 gene on malignant behavior of epithelial ovarian cancer cells and its related mechanism [J]. Journal of Hebei Medical University, 2022, 43(11): 1255-1260.
[3]	LIU Yang, KANG Lin, ZHENG Guo-na, ZHAO Huan-fen. Expression and clinical significance of CRIP1 gene in human ovarian cancer [J]. Journal of Hebei Medical University, 2021, 42(8): 904-908.
[4]	ZHANG Wei, GUO Bu-qing, HOU Yu-na, WANG Wei-wei, SHANG An-quan. Analysis of vaginal microecological characteristics and influencing factors in ovarian cancer patients with vaginitis [J]. Journal of Hebei Medical University, 2021, 42(8): 909-913.
[5]	MENG Tong-yu, ZHAO Tao, SONG Yu-xia, ZHAO Fang, LI Pan, ZHAO Jian. Expression of miRNA-107 in ovarian cancer tissues and its effect on VEGFA [J]. Journal of Hebei Medical University, 2021, 42(7): 818-822.
[6]	LI Xia, ZHANG Ke, MIN Nan. The mechanism of macrophage-derived exosomes inhibiting invasion and migration of epithelial ovarian cancer cells after TWEAK stimulation [J]. Journal of Hebei Medical University, 2021, 42(2): 163-166.
[7]	REZIYA·Kuerban, GULIMIRE·Buranjiang, GUZALINUER·Abulizi*. Mechanism of HOST2 lncRNA targeting miR-211 in ovarian cancer cell metastasis#br# [J]. Journal of Hebei Medical University, 2020, 41(9): 1058-1064.
[8]	MU Wei-hong, CHEN Wen-qi, PENG Yuan-yuan, ZHANG Jing*. The correlation between the expression of miR-141-3p and Cisplatin chemosensitivity of ovarian cancer cells#br# [J]. Journal of Hebei Medical University, 2020, 41(2): 167-171.
[9]	ZHANG Long-sheng, LU Yan, ZHANG Kai-hong, YANG Duo, YE Shu-jun, HUANG Zhi-liang. Comparison of the analgesic effect of quadratus lumborum block and transversus abdominis plane block in gynecological laparoscopic surgery [J]. Journal of Hebei Medical University, 2020, 41(12): 1450-1454.
[10]	ZUO Hongling1, YAN Xiaonan2, LIU Subin3, LI Xiuwen1, WANG Huilan1, XU Chunlin1, DU Hui1*. The effects of 17βestradiol on proliferation of ovarian clear cell carcinoma ES2 cell line and the possible mechanism [J]. Journal of Hebei Medical University, 2019, 40(9): 1029-1033.
[11]	FENG Yanping1, GUO Wei1, LIU Jing2, ZHANG Hongzhen2*, CHENG Jianxin3. Expression of Wip1 in ovarian serous cystadenocarcinoma tissues and its significance [J]. Journal of Hebei Medical University, 2018, 38(8): 929-933,937.
[12]	LIU Ying1, WANG Zeyang2, REN Wenjun2, LIU Lihua1, HOU Zhihua1, LIU Xinyan1*. Comparison between paclitaxel liposome and gemcitabine combined with cisplatin in the treatment of nonsmall cell lung cancer with hepatic metastases#br# [J]. Journal of Hebei Medical University, 2018, 38(7): 810-812,821.
[13]	HUANG Ping, LI Yanying, LI Lingling, QI Bingli, SU Mengya, ZHANG Jiyan. Effects of ATIP3aHMGA2ERK signaling pathway on cisplatin resistance in epithelial ovarian cancer [J]. Journal of Hebei Medical University, 2018, 38(10): 1179-1184.
[14]	CAO Hua. Effects of deep hyperthermia combined with systemic chemotherapy on advanced ovarian cancer and its effect on expression of ERCC1, βcatenin and βtubulin Ⅲ#br# [J]. Journal of Hebei Medical University, 2018, 38(1): 64-67.
[15]	SONG Yuxia, ZHAO Tao, WANG Hongwei, GUO Qing*, WANG Xuejuan. Differences in IL10 and IL12 expression of different tumorassociated macrophage subtypes in ascites of ovarian carcinoma [J]. Journal of Hebei Medical University, 2017, 37(6): 676-679.

Clinical observation of hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with advanced ovarian cancer#br#

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments